MedTrace Logo

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

NCT03347279 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1061

Last updated 2021-11-26

Study results available
· View outcomes & findings →

Summary

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma

Conditions

Interventions

BIOLOGICAL

Experimental: Tezepelumab

Tezepelumab subcutaneous injection

OTHER

Placebo

Placebo subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Andrew Menzies-Gow, MD · Royal Brompton Hospital, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-23
Primary Completion
2020-09-08
Completion
2020-11-12
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Brazil
  • Canada
  • France
  • Germany
  • Israel
  • Japan
  • Russia
  • Saudi Arabia
  • South Africa
  • South Korea
  • Taiwan
  • Ukraine
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03347279 on ClinicalTrials.gov